Please login to the form below

Not currently logged in
Email:
Password:

Shire wins EU licence for pancreatic cancer drug Onivyde

Combination treatment is the first approved for this patient population

ShireThe European Commission has approved Shire's Onivyde for the treatment of adults with metastatic adenocarcinoma of the pancreas, making it the first licensed treatment for this patient group in the EU.

Authorised as a second-line combination therapy, Onivyde (pegylated liposomal irinotecan hydrochloride trihydrate) will be administered with 5-fluorouracil (5-FU) and leucovorin (LV) in adult patients who have progressed following treatment with Lilly's Gemzar (gemcitabine).

The EU licensing follows FDA approval of the drug, after Shire won US marketing authorisation in October last year.

Data from the phase III trial NAPOLI-1 showed that the triple-drug treatment significantly extended overall survival at an average of 6.1 months compared to 4.2 months for the 5-FU and LV-only group.

As such Onivyde marks a first for this indication of pancreatic cancer patients for whom there has been little improvement in prognosis over the last twenty years.

Dr Philip Vickers, global head of R&D at Shire, commented: “The approval of Onivyde marks a significant step forward in Shire's focus to develop and commercialise treatments that represent the most promising science in oncology.”

Pancreatic cancer is the fourth leading cause of cancer death in Europe and seventh worldwide, with typically poor prognosis and an estimated 330,400 deaths each year.

The global pancreatic cancer market has seen rapid growth in recent years and is forecast to reach worldwide sales of $1.6bn by 2017, with the majority of sales attributed to Celgene's Abraxane (paclitaxel) in combination with Gemzar.

Article by
Rebecca Clifford

18th October 2016

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

A snapshot of… Exscientia
...
Patients are ready for virtual clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Keep your audiences close
How getting up close and personal with target audiences can fuel creativity...

Infographics